Inclusion Criteria:

- Histological diagnosis of epithelial adenocarcinoma of ovarian, tubal or peritoneal
origin.

- FIGO Stage III or IV prior to study.

- Serum CA125 level >35 U/mL prior to or at initial surgery. Alternatively, serum CA125
level > or = 100 U/mL following surgery or immunohistochemical evidence of tumor
tissue expressing CA125.

- Completed primary treatment following initial diagnosis, including chemotherapy
involving a cisplatin or carboplatin-based regimen.

- Functional Performance Status < or = 2 by ECOG scale.

- Medical assessment consistent with prognosis for an expected survival of at least 3
months.

- Voluntary participation, signed informed consent and willingness to complete all
study procedures.

Exclusion Criteria:

- No surgery (not including minor surgical procedures), chemotherapy, or radiotherapy
(whole abdomen, abdominopelvic or pelvic) within 4 weeks prior to first dose of study
drug.

- No known refractory or recurrent disease requiring chemotherapy during the 4 weeks
prior to, or planned 10 weeks after first study dose.

- Serum CA125 levels not >800 U/mL at baseline evaluation.

- No gross (clinically evident) ascites.

- No immunotherapy (interferons, tumor necrosis factor, other cytokines or biological
response modifiers, or BCG vaccines) within the previous 4 weeks of first study dose.

- No previous treatment with murine monoclonal antibodies for diagnostic or therapeutic
purposes or serum human anti-murine antibodies (HAMA) not above upper limit of normal
at baseline evaluation.

- Not on long-term chronic treatment with immunosuppressive drugs such as cyclosporin,
ACTH, or corticosteroids.

- Ovarian tumors must be of low malignant potential or with noninvasive disease.

- No concurrent malignancy (except non-melanoma of the skin or in situ carcinoma of
cervix), unless curative treatment was received and patient has been disease-free for
> or = 5 years.

- No known allergy to murine proteins, or prior documented anaphylactic reaction to any
drug, or known hypersensitivity to diphenhydramine or other antihistamines of similar
chemical structure.

- No previous splenectomy.

- No active autoimmune disease (e.g., rheumatoid arthritis, SLE, ulcerative colitis,
Chrohn's Disease, MS, ankylosing spondylitis).

- No recognized immunodeficiency disease including cellular immunodeficiencies,
hypogammaglobulinemia or dysgammaglobulinemia; no acquired, hereditary, or congenital
immunodeficiencies.

- No uncontrolled diseases or illness other than this cancer.

- No significant cardiovascular abnormalities including uncontrolled hypertension,
uncontrolled angina, uncontrolled arrhythmias, or CHF (NYHA Classes II-IV).

- No compromised hematopoietic function defined as a hemoglobin <10.0 g/dL or
lymphocyte count <300 mm3 or neutrophil count <1000 mm3 or platelet count <100,000
mm3.

- No hepatic dysfunction defined as a bilirubin above upper limit of normal, LDH, SGOT
and SGPT >2 times upper limits of normal, or albumin <3.5 g/dL.

- No renal dysfunction defined as serum creatinine above upper limit of normal.

- No pregnancy or breast-feeding (While pregnancy is unlikely in view of the disease
and previous surgery, patients who the investigator considers may be at risk of
pregnancy will have a pregnancy [beta-HCG] test and will be using a medically
approved contraceptive method.)

- No other investigational drugs within 30 days of enrollment.

- No contraindications present to the use of pressor agents.

- No HIV infection, or recent history of drug abuse, alcoholism, or hepatitis.